335 related articles for article (PubMed ID: 34094729)
1. Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review.
Vivekanandan G; Abubacker AP; Myneni R; Chawla HV; Iqbal A; Grewal A; Ndakotsu A; Khan S
Cureus; 2021 Apr; 13(4):e14764. PubMed ID: 34094729
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
[TBL] [Abstract][Full Text] [Related]
4. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
5. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
[TBL] [Abstract][Full Text] [Related]
6. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A
J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
[TBL] [Abstract][Full Text] [Related]
7. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
[TBL] [Abstract][Full Text] [Related]
9. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.
D'Amico E; Zanghì A; Leone C; Tumani H; Patti F
Drug Saf; 2016 Dec; 39(12):1163-1174. PubMed ID: 27696299
[TBL] [Abstract][Full Text] [Related]
10. Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Prosperini L; Scarpazza C; Imberti L; Cordioli C; De Rossi N; Capra R
J Neurovirol; 2017 Oct; 23(5):742-749. PubMed ID: 28791614
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica.
Paz SPC; Branco L; Pereira MAC; Spessotto C; Fragoso YD
Epidemiol Health; 2018; 40():e2018001. PubMed ID: 29370683
[TBL] [Abstract][Full Text] [Related]
12. Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review.
Bohra C; Sokol L; Dalia S
Cancer Control; 2017; 24(4):1073274817729901. PubMed ID: 28975841
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
14. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
15. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
Krämer J; Tenberge JG; Kleiter I; Gaissmaier W; Ruck T; Heesen C; Meuth SG
PLoS One; 2017; 12(4):e0174858. PubMed ID: 28406921
[TBL] [Abstract][Full Text] [Related]
16. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
17. PARP-1 deregulation in multiple sclerosis.
Meira M; Sievers C; Hoffmann F; Bodmer H; Derfuss T; Kuhle J; Haghikia A; Kappos L; Lindberg RL
Mult Scler J Exp Transl Clin; 2019; 5(4):2055217319894604. PubMed ID: 31897308
[TBL] [Abstract][Full Text] [Related]
18. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
Zhang Y; Wright C; Flores A
J Med Case Rep; 2018 Jul; 12(1):187. PubMed ID: 29960601
[TBL] [Abstract][Full Text] [Related]
19. Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis.
Herold TR; Jakl V; Graser A; Eibl-Lindner K
Clin Ophthalmol; 2012; 6():1131-3. PubMed ID: 22888211
[TBL] [Abstract][Full Text] [Related]
20. Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis.
Borie D; Kremer JM
Semin Arthritis Rheum; 2015 Oct; 45(2):163-6. PubMed ID: 26190565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
